Clinical trial registry record

Reversing Epigenetic & Other Markers of Senescence by Transfusing Young Plasma To Older Human Subjects

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Unknown.
Evidence
Registered phase 1, phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated January 17, 2018.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT03353597
Last registry update
January 17, 2018
Status
Unknown
Phase
Phase 1, Phase 2
Sponsor
Chandra Duggirala
Enrollment
2120
Countries
United States
Match confidence
80%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1, Phase 2
Study design
NA · SINGLE GROUP · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
2120
Population
ALL · 40 Years
Duration
2018-05-15 to 2022-12-15
Intervention
Plasma Transfusion
Comparator
Not reported
Outcomes measured
Biological age as assessed by DNA methylation levels, to calculate the Epigenetic age. — Baseline to end of Month 9.; Mental (Cognitive) Function — Baseline and Month 9; Lung (Pulmonary) Function — Baseline and Month 9; Kidney (Renal) Function — Baseline and Month 9; Muscle Strength — Baseline and Month 9; Telomere Length — Baseline and Month 9; Testosterone — Baseline and Month 9; Estrogen — Baseline and Month 9; DHEAS — Baseline and Month 9; IGF-1 — Baseline and Month 9; High Sensitivity C-Reactive Protein — Baseline and Month 9; P16INK4a (A marker of cellular aging) — Baseline and Month 9
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1, Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 80% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Young blood and parabiosis · 80%Title contains controlled term: young plasma. Title supplies longevity context: senescence. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

young blood parabiosis
Open primary sourceExport JSON